Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

MET in gastric cancer with liver metastasis: The relationship between MET amplification and Met overexpression in primary stomach tumors and liver metastasis.

Kim HS, Chon HJ, Kim H, Shin SJ, Wacheck V, Gruver AM, Kim JS, Rha SY, Chung HC.

J Surg Oncol. 2018 Jun;117(8):1679-1686. doi: 10.1002/jso.25097. Epub 2018 May 22.

PMID:
29790169
2.

A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer.

Bendell JC, Varghese AM, Hyman DM, Bauer TM, Pant S, Callies S, Lin J, Martinez R, Wickremsinhe E, Fink A, Wacheck V, Moore KN.

Clin Cancer Res. 2018 Jul 15;24(14):3253-3262. doi: 10.1158/1078-0432.CCR-17-3421. Epub 2018 Apr 10.

PMID:
29636360
3.

MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping.

Yan SB, Um SL, Peek VL, Stephens JR, Zeng W, Konicek BW, Liu L, Manro JR, Wacheck V, Walgren RA.

Invest New Drugs. 2018 Aug;36(4):536-544. doi: 10.1007/s10637-017-0545-x. Epub 2017 Nov 29.

4.

A non-randomized, open-label, single-arm, Phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancer.

Sakai D, Chung HC, Oh DY, Park SH, Kadowaki S, Kim YH, Tsuji A, Komatsu Y, Kang YK, Uenaka K, Wijayawardana SR, Wacheck V, Wang X, Yamamura A, Doi T.

Cancer Chemother Pharmacol. 2017 Dec;80(6):1197-1207. doi: 10.1007/s00280-017-3445-z. Epub 2017 Oct 25.

5.

A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer.

Rosen LS, Goldman JW, Algazi AP, Turner PK, Moser B, Hu T, Wang XA, Tuttle J, Wacheck V, Wooldridge JE, Banck M.

Clin Cancer Res. 2017 Apr 15;23(8):1910-1919. doi: 10.1158/1078-0432.CCR-16-1418. Epub 2016 Oct 10.

6.

Characterization of LY3023414, a Novel PI3K/mTOR Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor Growth.

Smith MC, Mader MM, Cook JA, Iversen P, Ajamie R, Perkins E, Bloem L, Yip YY, Barda DA, Waid PP, Zeckner DJ, Young DA, Sanchez-Felix M, Donoho GP, Wacheck V.

Mol Cancer Ther. 2016 Oct;15(10):2344-2356. Epub 2016 Jul 20.

7.

A phase I dose-escalation study of LY2875358, a bivalent MET antibody, given as monotherapy or in combination with erlotinib or gefitinib in Japanese patients with advanced malignancies.

Yoh K, Doi T, Ohmatsu H, Kojima T, Takahashi H, Zenke Y, Wacheck V, Enatsu S, Nakamura T, Turner K, Uenaka K.

Invest New Drugs. 2016 Oct;34(5):584-95. doi: 10.1007/s10637-016-0370-7. Epub 2016 Sep 1.

8.

LY2875358, a neutralizing and internalizing anti-MET bivalent antibody, inhibits HGF-dependent and HGF-independent MET activation and tumor growth.

Liu L, Zeng W, Wortinger MA, Yan SB, Cornwell P, Peek VL, Stephens JR, Tetreault JW, Xia J, Manro JR, Credille KM, Ballard DW, Brown-Augsburger P, Wacheck V, Chow CK, Huang L, Wang Y, Denning I, Davies J, Tang Y, Vaillancourt P, Lu J.

Clin Cancer Res. 2014 Dec 1;20(23):6059-70. doi: 10.1158/1078-0432.CCR-14-0543. Epub 2014 Sep 17.

9.

Circulating endothelial progenitor cells in castration resistant prostate cancer: a randomized, controlled, biomarker study.

Fuereder T, Wacheck V, Strommer S, Horak P, Gerschpacher M, Lamm W, Kivaranovic D, Krainer M.

PLoS One. 2014 Apr 22;9(4):e95310. doi: 10.1371/journal.pone.0095310. eCollection 2014.

10.

Phenotyping of human melanoma cells reveals a unique composition of receptor targets and a subpopulation co-expressing ErbB4, EPO-R and NGF-R.

Mirkina I, Hadzijusufovic E, Krepler C, Mikula M, Mechtcheriakova D, Strommer S, Stella A, Jensen-Jarolim E, Höller C, Wacheck V, Pehamberger H, Valent P.

PLoS One. 2014 Jan 29;9(1):e84417. doi: 10.1371/journal.pone.0084417. eCollection 2014.

11.

The PI3-kinase/mTOR-targeting drug NVP-BEZ235 inhibits growth and IgE-dependent activation of human mast cells and basophils.

Blatt K, Herrmann H, Mirkina I, Hadzijusufovic E, Peter B, Strommer S, Hoermann G, Mayerhofer M, Hoetzenecker K, Klepetko W, Ghanim V, Marth K, Füreder T, Wacheck V, Valenta R, Valent P.

PLoS One. 2012;7(1):e29925. doi: 10.1371/journal.pone.0029925. Epub 2012 Jan 27.

12.

A comparative small-animal PET evaluation of [11C]tariquidar, [11C]elacridar and (R)-[11C]verapamil for detection of P-glycoprotein-expressing murine breast cancer.

Wanek T, Kuntner C, Bankstahl JP, Bankstahl M, Stanek J, Sauberer M, Mairinger S, Strommer S, Wacheck V, Löscher W, Erker T, Müller M, Langer O.

Eur J Nucl Med Mol Imaging. 2012 Jan;39(1):149-59. doi: 10.1007/s00259-011-1941-7. Epub 2011 Oct 8.

13.

Does endovenous laser ablation induce endothelial damage at the saphenofemoral junction?

Heere-Ress E, Veensalu M, Wacheck V, Tzaneva S, Kittler H, Kapiotis S, Wolzt M, Böhler K.

Dermatol Surg. 2011 Oct;37(10):1456-63. doi: 10.1111/j.1524-4725.2011.02106.x. Epub 2011 Jul 26.

PMID:
21790851
14.

Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K/mTOR target inhibition but with [18F]FLT uptake.

Fuereder T, Wanek T, Pflegerl P, Jaeger-Lansky A, Hoeflmayer D, Strommer S, Kuntner C, Wrba F, Werzowa J, Hejna M, Müller M, Langer O, Wacheck V.

Clin Cancer Res. 2011 Aug 15;17(16):5322-32. doi: 10.1158/1078-0432.CCR-10-1659. Epub 2011 Jun 28.

15.

Dose study of the multikinase inhibitor, LY2457546, in patients with relapsed acute myeloid leukemia to assess safety, pharmacokinetics, and pharmacodynamics.

Wacheck V, Lahn M, Dickinson G, Füreder W, Meyer R, Herndlhofer S, Füreder T, Dorfner G, Pillay S, André V, Burkholder TP, Akunda JK, Flye-Blakemore L, Van Bockstaele D, Schlenk RF, Sperr WR, Valent P.

Cancer Manag Res. 2011;3:157-75. doi: 10.2147/CMR.S19341. Epub 2011 May 10.

16.

Sphingosine kinase 1 is a relevant molecular target in gastric cancer.

Fuereder T, Hoeflmayer D, Jaeger-Lansky A, Rasin-Streden D, Strommer S, Fisker N, Hansen BJ, Crevenna R, Wacheck V.

Anticancer Drugs. 2011 Mar;22(3):245-52.

PMID:
21360847
17.

Vertical inhibition of the mTORC1/mTORC2/PI3K pathway shows synergistic effects against melanoma in vitro and in vivo.

Werzowa J, Koehrer S, Strommer S, Cejka D, Fuereder T, Zebedin E, Wacheck V.

J Invest Dermatol. 2011 Feb;131(2):495-503. doi: 10.1038/jid.2010.327. Epub 2010 Nov 4.

18.

mTOR pathway inhibitors in cancer therapy: moving past rapamycin.

Wacheck V.

Pharmacogenomics. 2010 Sep;11(9):1189-91. doi: 10.2217/pgs.10.113. No abstract available.

19.

mTOR inhibition by everolimus counteracts VEGF induction by sunitinib and improves anti-tumor activity against gastric cancer in vivo.

Fuereder T, Jaeger-Lansky A, Hoeflmayer D, Preusser M, Strommer S, Cejka D, Koehrer S, Crevenna R, Wacheck V.

Cancer Lett. 2010 Oct 28;296(2):249-56. doi: 10.1016/j.canlet.2010.04.015. Epub 2010 May 14.

PMID:
20471160
20.

Effects of vatalanib on tumor growth can be potentiated by mTOR blockade in vivo.

Jaeger-Lansky A, Cejka D, Ying L, Preusser M, Hoeflmayer D, Fuereder T, Koehrer S, Wacheck V.

Cancer Biol Ther. 2010 Jun 1;9(11):919-27. Epub 2010 Jun 18.

PMID:
20404549
21.

A novel type of influenza vaccine: safety and immunogenicity of replication-deficient influenza virus created by deletion of the interferon antagonist NS1.

Wacheck V, Egorov A, Groiss F, Pfeiffer A, Fuereder T, Hoeflmayer D, Kundi M, Popow-Kraupp T, Redlberger-Fritz M, Mueller CA, Cinatl J, Michaelis M, Geiler J, Bergmann M, Romanova J, Roethl E, Morokutti A, Wolschek M, Ferko B, Seipelt J, Dick-Gudenus R, Muster T.

J Infect Dis. 2010 Feb 1;201(3):354-62. doi: 10.1086/649428.

PMID:
20039806
22.

Differential role of circulating endothelial progenitor cells in cirrhotic patients with or without hepatocellular carcinoma.

Sieghart W, Fellner S, Reiberger T, Ulbrich G, Ferlitsch A, Wacheck V, Peck-Radosavljevic M.

Dig Liver Dis. 2009 Dec;41(12):902-6. doi: 10.1016/j.dld.2009.04.013. Epub 2009 Jun 4.

PMID:
19501032
23.

FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivo.

Cejka D, Kuntner C, Preusser M, Fritzer-Szekeres M, Fueger BJ, Strommer S, Werzowa J, Fuereder T, Wanek T, Zsebedics M, Mueller M, Langer O, Wacheck V.

Br J Cancer. 2009 Jun 2;100(11):1739-45. doi: 10.1038/sj.bjc.6605076. Epub 2009 May 12.

24.

Characterization of NVX-207, a novel betulinic acid-derived anti-cancer compound.

Willmann M, Wacheck V, Buckley J, Nagy K, Thalhammer J, Paschke R, Triche T, Jansen B, Selzer E.

Eur J Clin Invest. 2009 May;39(5):384-94. doi: 10.1111/j.1365-2362.2009.02105.x.

PMID:
19309323
25.

mTOR inhibition sensitizes gastric cancer to alkylating chemotherapy in vivo.

Cejka D, Preusser M, Fuereder T, Sieghart W, Werzowa J, Strommer S, Wacheck V.

Anticancer Res. 2008 Nov-Dec;28(6A):3801-8.

26.

Suppression of mTOR complex 2-dependent AKT phosphorylation in melanoma cells by combined treatment with rapamycin and LY294002.

Werzowa J, Cejka D, Fuereder T, Dekrout B, Thallinger C, Pehamberger H, Wacheck V, Pratscher B.

Br J Dermatol. 2009 May;160(5):955-64. doi: 10.1111/j.1365-2133.2008.08991.x. Epub 2008 Dec 16.

PMID:
19120326
27.

Everolimus (RAD001) and anti-angiogenic cyclophosphamide show long-term control of gastric cancer growth in vivo.

Cejka D, Preusser M, Woehrer A, Sieghart W, Strommer S, Werzowa J, Fuereder T, Wacheck V.

Cancer Biol Ther. 2008 Sep;7(9):1377-85. Epub 2008 Sep 2.

PMID:
18708754
28.

Characterization of NKIP: a novel, Na+/K+-ATPase interacting protein mediates neural differentiation and apoptosis.

Pratscher B, Friedrich C, Goger W, Allen M, Fink D, Thallinger C, Wolschek M, Frei K, Schöfer C, Pehamberger H, Wacheck V, Sorensen PH, Müller M, Jansen B, Lucas T.

Exp Cell Res. 2008 Feb 1;314(3):463-77. Epub 2007 Nov 24.

PMID:
18096156
29.

Bcl-2 downregulation sensitizes nonsmall cell lung cancer cells to cisplatin, but not to docetaxel.

Losert D, Pratscher B, Soutschek J, Geick A, Vornlocher HP, Müller M, Wacheck V.

Anticancer Drugs. 2007 Aug;18(7):755-61.

PMID:
17581297
30.

A clinical trial on absorption and N-acetylation of oral and rectal mesalazine.

Dilger K, Trenk D, Rössle M, Cap M, Zähringer A, Wacheck V, Remmler C, Cascorbi I, Kreisel W, Novacek G.

Eur J Clin Invest. 2007 Jul;37(7):558-65.

PMID:
17576207
31.

Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation.

Sieghart W, Fuereder T, Schmid K, Cejka D, Werzowa J, Wrba F, Wang X, Gruber D, Rasoul-Rockenschaub S, Peck-Radosavljevic M, Wacheck V.

Transplantation. 2007 Feb 27;83(4):425-32.

PMID:
17318075
32.

Expression of the target receptor CD33 in CD34+/CD38-/CD123+ AML stem cells.

Hauswirth AW, Florian S, Printz D, Sotlar K, Krauth MT, Fritsch G, Schernthaner GH, Wacheck V, Selzer E, Sperr WR, Valent P.

Eur J Clin Invest. 2007 Jan;37(1):73-82.

PMID:
17181570
33.

Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412.

Aichberger KJ, Mayerhofer M, Gleixner KV, Krauth MT, Gruze A, Pickl WF, Wacheck V, Selzer E, Müllauer L, Agis H, Sillaber C, Valent P.

Blood. 2007 Apr 1;109(7):3031-41.

34.

[Oligonucleotide therapeutics - an emerging novel class of compounds].

Wacheck V.

Wien Med Wochenschr. 2006 Sep;156(17-18):481-7. Review. German.

PMID:
17041803
35.

Mcl-1 is a relevant molecular target for antisense oligonucleotide strategies in gastric cancer cells.

Wacheck V, Cejka D, Sieghart W, Losert D, Strommer S, Crevenna R, Monia BP, Selzer E.

Cancer Biol Ther. 2006 Oct;5(10):1348-54. Epub 2006 Oct 26.

PMID:
16969094
36.

Antisense molecules for targeted cancer therapy.

Wacheck V, Zangemeister-Wittke U.

Crit Rev Oncol Hematol. 2006 Jul;59(1):65-73. Epub 2006 Jun 5. Review.

PMID:
16750913
37.

Short interfering RNA (siRNA): tool or therapeutic?

Cejka D, Losert D, Wacheck V.

Clin Sci (Lond). 2006 Jan;110(1):47-58. Review.

PMID:
16336204
38.

Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy.

Sieghart W, Losert D, Strommer S, Cejka D, Schmid K, Rasoul-Rockenschaub S, Bodingbauer M, Crevenna R, Monia BP, Peck-Radosavljevic M, Wacheck V.

J Hepatol. 2006 Jan;44(1):151-7. Epub 2005 Oct 25.

PMID:
16289418
39.

Thalidomide enhances the anti-tumor activity of standard chemotherapy in a human melanoma xenotransplatation model.

Heere-Ress E, Boehm J, Thallinger C, Hoeller C, Wacheck V, Birner P, Wolff K, Pehamberger H, Jansen B.

J Invest Dermatol. 2005 Aug;125(2):201-6. Erratum in: J Invest Dermatol. 2005 Dec;125(6):1320.

40.

Mcl-1 blocks radiation-induced apoptosis and inhibits clonogenic cell death.

Skvara H, Thallinger C, Wacheck V, Monia BP, Pehamberger H, Jansen B, Selzer E.

Anticancer Res. 2005 Jul-Aug;25(4):2697-703.

41.

Clusterin regulates drug-resistance in melanoma cells.

Hoeller C, Pratscher B, Thallinger C, Winter D, Fink D, Kovacic B, Sexl V, Wacheck V, Gleave ME, Pehamberger H, Jansen B.

J Invest Dermatol. 2005 Jun;124(6):1300-7.

42.

Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.

Aichberger KJ, Mayerhofer M, Krauth MT, Skvara H, Florian S, Sonneck K, Akgul C, Derdak S, Pickl WF, Wacheck V, Selzer E, Monia BP, Moriggl R, Valent P, Sillaber C.

Blood. 2005 Apr 15;105(8):3303-11. Epub 2004 Dec 30.

43.

Strategies for designing clinical trials for oligonucleotide therapeutics.

Wacheck V.

Drug Discov Today. 2004 Nov 1;9(21):918-23. Review.

PMID:
15501726
44.
45.
46.

Loss of novel mda-7 splice variant (mda-7s) expression is associated with metastatic melanoma.

Allen M, Pratscher B, Roka F, Krepler C, Wacheck V, Schöfer C, Pehamberger H, Müller M, Lucas T.

J Invest Dermatol. 2004 Sep;123(3):583-8.

47.

Mcl-1 is a novel therapeutic target for human sarcoma: synergistic inhibition of human sarcoma xenotransplants by a combination of mcl-1 antisense oligonucleotides with low-dose cyclophosphamide.

Thallinger C, Wolschek MF, Maierhofer H, Skvara H, Pehamberger H, Monia BP, Jansen B, Wacheck V, Selzer E.

Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4185-91.

48.

Combination allele-specific real-time PCR for differentiation of beta 2-adrenergic receptor coding single-nucleotide polymorphisms.

Lucas T, Losert D, Allen M, Halaschek-Wiener J, Pratscher B, Friedrich C, Wolschek M, Fuchsjäger-Mayrl G, Schmetterer L, Pehamberger H, Müller M, Wacheck V.

Clin Chem. 2004 Apr;50(4):769-72. No abstract available.

49.

CpG oligonucleotides elicit antitumor responses in a human melanoma NOD/SCID xenotransplantation model.

Krepler C, Wacheck V, Strommer S, Hartmann G, Polterauer P, Wolff K, Pehamberger H, Jansen B.

J Invest Dermatol. 2004 Feb;122(2):387-91.

50.

Small interfering RNA targeting bcl-2 sensitizes malignant melanoma.

Wacheck V, Losert D, Günsberg P, Vornlocher HP, Hadwiger P, Geick A, Pehamberger H, Müller M, Jansen B.

Oligonucleotides. 2003;13(5):393-400.

PMID:
15000830

Supplemental Content

Loading ...
Support Center